Key Metrics of KALA BIO Inc.
Revenue$0▼ 100.0% YoYFY 2023
Operating income−$39.7M▲ 51.5% YoY
Net profit−$42.2M▲ 5.9% YoY
Shareholders' equity$7.5M
Market cap$3.7MKALA · $0.19
Competitors10identified
About KALA BIO Inc.
Sectors
Company details
- Founded
- 2017
- Listed
- Nasdaq: KALA (since 2017)
Operational Areas of KALA BIO Inc.
Pharmaceuticals & Healthcare›Biotechnology & Vaccines
Company summary
Legal nameKALA BIO Inc.
TickerKALA
ExchangeNasdaq
CountryUnited States
SEC CIK0001479419
Listed since2017
IndustryBiotechnology: Pharmaceutical Preparations
SectorPharmaceuticals & Healthcare · Biotechnology & Vaccines
Website—
US market & SEC filings
KALA · Nasdaq · SEC CIK 0001479419
Last price · 27 Oct 2026
$0.19
+2.48%
Market cap$3.7M
P/E—On FY 2023 diluted EPS
Volume207,838
SectorHealth CareBiotechnology: Pharmaceutical Preparations
Country · IPOUnited StatesListed 2017
KALA share price
Premium
Annual results (SEC EDGAR)
Revenue, operating income, net income, EPS, cash flow, assets, liabilities, equity and debt for every year filed with the SEC are part of the premium plan.
Sign in to continue See plans & pricingVendor checks & payment capacity
Sign in with access to company financials to review vendor evidence.
Registered office and contact
Registered office—
GSTIN—
Email—
Website—
Members / shareholders—
Directors and key people
Directors are read from the MGT-7 annual return and AOC-4 signatories.
Competitors of KALA BIO Inc.
Competitors10identified
Countries1most in United States
Top competitors by location
| Company | Description | Domain | Founded | Location |
|---|---|---|---|---|
| Part of Vertex Pharmaceuticals. | vrtx.com | 1991 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | modernatx.com | 2018 | United States | |
 Becton Dickinson |
Biotechnology & Vaccines · Pharmaceuticals & Healthcare | bd.com | — | United States |
| Part of Illumina. | illumina.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | guardanthealth.com | 2018 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | revvity.com | — | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | exelixis.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | neurocrine.com | 1996 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | biomarin.com | 1999 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | bio-rad.com | 1980 | United States |
Similar companies
A
Anthem Biosciences (India)Pharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
I
International Biotech Park LimitedPharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
B
Bharat Immunologicals And Biologicals Corporation LimitedPharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
H
Hester Biosciences LimitedPharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
M
Medicamen Biotech LimitedPharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
K
Kbk Biotech Private LimitedPharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
R
Royalty Pharma plcPharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
A
argenx SEPharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
Charges (secured borrowings)
0 registered charges. Lenders, amounts and dates are part of the premium plan.
Statutory auditors
Auditors are read from the AOC-4 auditor's report section.
Business activities and related parties
Principal business activities and related-party transactions are read from MGT-7 and AOC-4 filings.
Filings
No filings on record yet.